Delek Group Ltd. raised its stake in Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) by 23.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 62,437 shares of the specialty pharmaceutical company’s stock after purchasing an additional 11,741 shares during the quarter. Delek Group Ltd. owned 0.11% of Foamix Pharmaceuticals worth $145,000 at the end of the most recent reporting period.
Several other hedge funds also recently made changes to their positions in FOMX. JPMorgan Chase & Co. raised its holdings in shares of Foamix Pharmaceuticals by 24.3% in the second quarter. JPMorgan Chase & Co. now owns 112,536 shares of the specialty pharmaceutical company’s stock worth $270,000 after acquiring an additional 22,027 shares during the last quarter. ARK Investment Management LLC grew its position in shares of Foamix Pharmaceuticals by 25.0% in the second quarter. ARK Investment Management LLC now owns 146,745 shares of the specialty pharmaceutical company’s stock valued at $349,000 after purchasing an additional 29,378 shares during the period. Knott David M grew its position in shares of Foamix Pharmaceuticals by 68.0% in the first quarter. Knott David M now owns 346,346 shares of the specialty pharmaceutical company’s stock valued at $1,299,000 after purchasing an additional 140,146 shares during the period. Handelsbanken Fonder AB grew its position in shares of Foamix Pharmaceuticals by 6.3% in the first quarter. Handelsbanken Fonder AB now owns 680,000 shares of the specialty pharmaceutical company’s stock valued at $2,550,000 after purchasing an additional 40,000 shares during the period. Finally, IPG Investment Advisors LLC purchased a new stake in shares of Foamix Pharmaceuticals in the first quarter valued at $231,000. Institutional investors own 47.19% of the company’s stock.
Shares of NASDAQ FOMX opened at $3.42 on Friday. The stock’s 50 day moving average price is $2.83 and its two-hundred day moving average price is $3.02. Foamix Pharmaceuticals Ltd has a 52-week low of $1.97 and a 52-week high of $6.48. The stock has a market capitalization of $208.62 million, a P/E ratio of -2.01 and a beta of 1.53.
Foamix Pharmaceuticals (NASDAQ:FOMX) last announced its quarterly earnings data on Wednesday, August 7th. The specialty pharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.07). Foamix Pharmaceuticals had a negative net margin of 2,115.11% and a negative return on equity of 75.99%. As a group, research analysts anticipate that Foamix Pharmaceuticals Ltd will post -1.64 EPS for the current fiscal year.
A number of brokerages have recently commented on FOMX. ValuEngine raised Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Barclays began coverage on Foamix Pharmaceuticals in a research report on Tuesday, June 11th. They set an “overweight” rating and a $10.00 price target for the company. Bank of America reissued a “buy” rating and set a $11.00 price target on shares of Foamix Pharmaceuticals in a research report on Friday, August 9th. Zacks Investment Research downgraded Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, August 22nd. Finally, HC Wainwright set a $12.00 target price on Foamix Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, May 28th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $13.96.
In other news, CFO Ilan Hadar sold 9,420 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $3.50, for a total transaction of $32,970.00. Following the sale, the chief financial officer now directly owns 123,671 shares in the company, valued at approximately $432,848.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 22,222 shares of company stock worth $69,507 over the last quarter. Insiders own 2.95% of the company’s stock.
About Foamix Pharmaceuticals
Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea.
Featured Story: Leveraged Buyout (LBO) Explained
Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.